首页> 外国专利> METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING INFLAMMATORY BOWEL DISEASE AND NONALCOHOLIC FATTY LIVER DISEASE

METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING INFLAMMATORY BOWEL DISEASE AND NONALCOHOLIC FATTY LIVER DISEASE

机译：预防和治疗炎症性肠病和非酒精性脂肪肝疾病的方法和组合物

页面导航

摘要
著录项
相似文献

摘要

The present technology relates to methods for preventing or treating inflammatory bowel disease or nonalcoholic fatty liver disease comprising administering an effective amount of a prebiotic composition (e.g., psyllium) or a probiotic composition (e.g., Lactobacillus johnsonii) to a subject in need thereof. Kits for use in practicing the methods are also provided.

机译：本技术涉及用于预防或治疗炎性肠疾病或非酒精性脂肪肝疾病的方法，包括将有效量的益生元组合物（例如车前草）或益生菌组合物（例如约翰逊乳杆菌）施用至有需要的对象。还提供了用于实施该方法的试剂盒。 展开▼

著录项

公开/公告号WO2020041581A1

专利类型

公开/公告日2020-02-27

原文格式PDF

申请/专利权人 CORNELL UNIVERSITY;
展开▼

申请/专利号WO2019US47692

发明设计人 DANNENBERG ANDREW J.;MONTROSE DAVID C.;
展开▼

申请日2019-08-22

分类号A61K35/741;A61K35/745;A61K35/747;

国家 WO

入库时间 2022-08-21 11:13:16

相似文献

专利

外文文献

中文文献

1. 一种预防和治疗非酒精性脂肪肝的组合物及其用途 [P] . 中国专利： CN104435147A . 2015-03-25

2. 一种用于预防和治疗非酒精性脂肪肝的药物组合物及其用途 [P] . 中国专利： CN103479635A . 2014-01-01

3. methods for preventing or treating inflammatory bowel disease in a feline, and for determining if a feline suffers from inflammatory bowel disease, kit, means for communicating information or instructions, using docosahexaenoic acid and optionally at least one fatty acid , e, Method for decreasing the level of neutrophils and cd4 + lymphocytes in a feline [P] . BRPI0620719A2 . 2012-09-18

机译：预防或治疗猫科动物炎症性肠病的方法以及确定猫科动物是否患有炎症性肠病的试剂盒，试剂盒，使用二十二碳六烯酸和任选的至少一种脂肪酸的信息或说明书传达方法，例如，猫中性粒细胞和cd4 +淋巴细胞的水平

4. Compound, isomers to be enantiomerically pure thereof, pharmaceutical composition and methods of inhibiting pde4 and mmp, modulating tnf-alpha production, treating or preventing mds, treating myeloproliferative disease, unwanted angiogenesis, cancer, a disease, lung inflammation , depression, chronic obstructive pulmonary disorder, inflammatory bowel disease, atopic dermatitis, psoriasis, crohn's disease, rheumatoid arthritis, asthma, multiple sclerosis and heart disease in a mammal and to treat, prevent or control complex regional pain syndrome [P] . BR0317885A . 2005-12-06

机译：化合物，其对映体纯的异构体，抑制pde4和mmp，调节tnf-α产生，治疗或预防mds，治疗骨髓增生性疾病，不良血管生成，癌症，疾病，肺部炎症，抑郁症，慢性阻塞性肺的药物组合物和方法哺乳动物的疾病，炎症性肠病，特应性皮炎，牛皮癣，克罗恩病，类风湿性关节炎，哮喘，多发性硬化症和心脏病，以治疗，预防或控制复杂的局部疼痛综合征

5. A composition for improving, preventing and treating of anti-inflammatory, obesity and nonalcoholic fatty liver disease comprising Artemisia Annua extract, Magnolia Obovata Bark extract and its mixed extracts [P] . KR20210079828A . 2021-06-30

机译：一种用于改善，预防和治疗抗炎，肥胖和非酒精性脂肪肝疾病的组合物，其包含蒿属植物，木兰obovata Bark提取物及其混合提取物

1. Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients? [J] . Sartini Alessandro, Gitto Stefano, Villa Erica Digestive Diseases and Sciences . 2017,第9期

2. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis [J] . Peter Hoffmann, Victoria Jung, Annika Gauss, World Journal of Gastroenterology . 2020,第46期

3. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. [J] . Chiara Saroli Palumbo, Sophie Restellini, Che-Yung Chao, Inflammatory bowel diseases . 2019,第1期

4. Site-Directed Polymer-Drug Complexes for Modulating Gut Innate Immune System to Prevent/Treat Inflammatory Bowel Diseases(IBD) [C] . KesharwaniS., AhmadR., RajputM. Bioengineering and Translational Medicine Conference . 2018

5. Hepatoprotection of Vitamin E and Green Tea on Oxidative Stress and Inflammatory Responses In Animal Models of Obesity-Triggered Nonalcoholic Fatty Liver Disease. [D] . Chung, Min-Yu. 2011

6. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis [O] . Peter Hoffmann, Victoria Jung, Rouven Behnisch, 2020

7. Poster session 2Morphogenetic mechanisms290MiR-133 regulates retinoic acid pathway during early cardiac chamber specification291Bmp2 regulates atrial differentiation through miR-130 during early heart looping formationDevelopmental genetics294Association of deletion allele of insertion/deletion polymorphism in alpha 2B adrenoceptor gene and hypertension with or without type 2 diabetes mellitus295Association of G1359A polymorphism of the endocannabinoid type 1 receptor (CNR1) with coronary artery disease (CAD) with type 2 diabetes mellitusCell growth, differentiation and stem cells - Vascular298Gamma-secretase inhibitor prevents proliferation and migration of ductus arteriosus smooth muscle cells: a role of Notch signaling in postnatal closure of ductus arteriosus299Mesenchymal stromal-like cells (MLCs) derived from induced pluripotent stem (iPS) cells: a promising therapeutic option to promote neovascularization300Sonic Hedgehog promotes mesenchymal stem cell differentiation to vascular smooth muscle cells in cardiovacsular disease301Proinflammatory cytokine secretion and epigenetic modification in endothelial cells treated LPS-GinfivalisCell death and apoptosis - Vascular304Mitophagy acts as a safeguard mechanism against human vascular smooth muscle cell apoptosis induced by atherogenic lipidsTranscriptional control and RNA species - Vascular307MicroRNA-34a role in vascular calcification308Local delivery of a miR-146a inhibitor utilizing a clinically applicable approach attenuates neointima formation after vascular injury309Long noncoding RNA landscape of hypoxic endothelial cells310Specific circulating microRNAs levels associate with hypertension, hyperglycemia and dysfunctional HDL in acute coronary syndrome patientsCytokines and cellular inflammation - Vascular313Phosphodiesterase5A up-regulation in vascular endothelium under pro-inflammatory conditions: a newly disclosed anti-inflammatory activity for the omega-3polyunsaturated aatty acid docosahexaenoic acid314Cardiovascular risk modifying with extra-low dose anticytokine drugs in rhematoid arthritis315Conversion of human M-CSF macrophages into foam cells reduces their proinflammatory responses to classical M1-polarizing activation316Lymphocytic myocarditis coincides with increased plaque inflammation and plaque hemorrhage in coronary arteries, facilitating myocardial infarction317Serum osteoprotegerin level predictsdeclined numerous of circulating endothelial- derived and mononuclear-derived progenitor cells in patients with metabolic syndromeGrowth factors and neurohormones - Vascular320Effect of gastrin-releasing peptide (GRP) on vascular inflammationSignal transduction - Heart323A new synthetic peptide regulates hypertrophy in vitro through means of the inhibition of nfkb324Inducible fibroblast-specific knockout of p38 alpha map kinase is cardioprotective in a mouse model of isoproterenol-induced cardiac hypertrophy325Regulation of beta-adrenoceptor-evoked inotropic responses by inhibitory G protein, adenylyl cyclase isoforms 5 and 6 and phosphodiesterases326Binding to RGS3 and stimulation of M2 muscarinic acetylcholine receptors modulates the substrate specificity of p190RhoGAP in cardiac myocytes327Cardiac regulation of post-translational modifications, parylation and deacetylation in LMNA dilated cardiomyopathy mouse model328Beta-adrenergic regulation of the b56delta/pp2a holoenzyme in cardiac myocytes through b56delta phosphorylation at serine 573Nitric oxide and reactive oxygen species - Vascular331Oxidative stress-induced miR-200c disrupts the regulatory loop among SIRT1, FOXO1 and eNOS332Antioxidant therapy prevents oxidative stress-induced endothelial dysfunction and Enhances Wound Healing333Morphological and biochemical characterization of red blood cell in coronary artery diseaseCytoskeleton and mechanotransduction - Heart336Novel myosin activator, JSH compounds, increased myocardial contractility without chronotropic effect in ratsExtracellular matrix and fibrosis - Vascular339Ablation of Toll-like receptor 9 causes cardiac rupture after myocardial infarction by attenuating proliferation and differentiation of cardiac fibroblasts340Altered vascular remodeling in the mouse hind limb ischemia model in Factor VII activating protease (FSAP) deficiencyVasculogenesis, angiogenesis and arteriogenesis343Pro-angiogenic effects of proly-hydroxylase inhibitors and their potential for use in a novel strategy of therapeutic angiogenesis for coronary total occlusion344Nrf2 drives angiogenesis in transcription-independent manner: new function of the master regulator of oxidative stress response345Angiogenic gene therapy, despite efficient vascular growth, is not able to improve muscle function in normoxic or chronically ischemic rabbit hindlimbs -role of capillary arterialization and shunting346Effect of PAR-1 inhibition on collateral vessel growth in the murine hind limb model347Quaking is a key regulator of endothelial cell differentiation, neovascularization and angiogenesis348"Emerging angiogenesis" in the chick chorioallantoic membrane (CAM). An in vivo study349Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis in vitro and in vivo via EMMPRINEndothelium352Reciprocal regulation of GRK2 and bradykinin receptor stimulation modulate Ca2+ intracellular level in endothelial cells353The roles of bone morphogenetic proteins 9 and 10 in endothelial inflammation and atherosclerosis354The contribution of GPR55 to the L-alpha-lysophosphatidylinositol-induced vasorelaxation in isolated human pulmonary arteries355The endothelial protective ACE inhibitor Zofenoprilat exerts anti-inflammatory activities through H2S production356A new class of glycomimetic drugs to prevent free fatty acid-induced endothelial dysfunction357Endothelial progenitor cells to apoptotic endothelial cell-derived microparticles ration differentiatesas preserved from reduced ejection fractionheart failure358Proosteogenic genes are activated in endothelial cells of patients with thoracic aortic aneurysm359Endothelin ETB receptors mediate relaxing responses to insulin in pericardial resistance arteries from patients with cardiovascular disease (CVD)Smooth muscle and pericytes362CX3CR1 positive myeloid cells regulate vascular smooth muscle tone by inducing calcium oscillations via activation of IP3 receptors363A novel function of PI3Kg on cAMP regulation, role in arterial wall hyperplasia through modulation of smooth muscle cells proliferation364NRP1 and NRP2 play important roles in the development of neointimal hyperplasia in vivo365Azithromycin induces autophagy in aortic smooth muscle cellsCoagulation, thrombosis and platelets368The real time in vivo evaluation of platelet-dependent aldosterone prothrombotic action in mice369Development of a method for in vivo detection of active thrombi in mice370The antiplatelet effects of structural analogs of the taurine chloramine371The influence of heparin anticoagulant drugs on functional state of human platelets372Regulation of platelet aggregation and adenosine diphosphate release by d dimer in acute coronary syndrome (in vitro study)Oxygen sensing, ischaemia and reperfusion375Sirtuin 5 mediates brain injury in a mouse model of cerebral ischemia-reperfusion376Abscisic acid: a new player in cardiomyocyte protection from ischaemia?377Protective effects of ultramicronized palmitoylethanolamide (PEA-um) in myocardial ischaemia and reperfusion injury in vivo378Identification of stem cell-derived cardiomyocytes using cardiac specific markers and additional testing of these cells in simulated ischemia/reperfusion system379Single-dose intravenous metformin treatment could afford significant protection of the injured rat kidney in an experimental model of ischemia-reperfusion380Cardiotoxicity of long acting muscarinic receptor antagonists used for chronic obstructive pulmonary disease381Dependence antioxidant potential on the concentration of amino acids382The impact of ischemia-reperfusion on physiological parameters,apoptosis and ultrastructure of rabbit myocardium with experimental aterosclerosisMitochondria and energetics385MicroRNA-1 dependent regulation of mitochondrial calcium uniporter (MCU) in normal and hypertrophied hearts386Mitochondrial homeostasis and cardioprotection: common targets for desmin and aB-crystallin387Overexpression of mitofusin-2 (Mfn2) and associated mitochondrial dysfunction in the diabetic heart388NO-dependent prevention of permeability transition pore (MPTP) opening by H2S and its regulation of Ca2+ accumulation in rat heart mitochondria389G protein coupled receptor kinase 2 (GRK2) is fundamental in recovering mitochondrial morphology and function after exposure to ionizing radiation (IR)Gender issues392Sex differences in pulmonary vascular control; focus on the nitric oxide pathwayAging395Heart failure with preserved ejection fraction develops when feeding western diet to senescence-accelerated mice396Cardiovascular markers as predictors of cognitive decline in elderly hypertensive patients397Changes in connexin43 in old rats with volume overload chronic heart failureGenetics and epigenetics400Calcium content in the aortic valve is associated with 1G>2G matrix metalloproteinase 1 polymorphism401Neuropeptide receptor gene s (NPSR1) polymorphism and sleep disturbances402Endothelin-1 gene Lys198Asn polymorphism in men with essential hypertension complicated and uncomplicated with chronic heart failure403Association of common polymorphisms of the lipoprotein lipase and pon1 genes with the metabolic syndrome in a sample of community participantsGenomics, proteomics, metabolomics, lipidomics and glycomics405Gene expression quantification using multiplexed color-coded probe pairs to determine RNA content in sporadic cardiac myxoma406Large-scale phosphorylation study of the type 2 diabetic heart subjected to ischemia / reperfusion injury407Transcriptome-based identification of new anti-inflammatory properties of the olive oil hydroxytyrosol in vascular endothelial cell under basal and proinflammatory conditions408Gene polymorphisms combinations and risk of myocardial infarctionComputer modelling, bioinformatics and big data411Comparison of the repolarization reserve in three state-of-the-art models of the human ventricular action potentialMetabolism, diabetes mellitus and obesity414Endothelial monocyte-activating polypeptide-II improves heart function in type -I Diabetes mellitus415Admission glucose level is independent predictor of impaired left ventricular function in patients with acute myocardial infarction: a two dimensional speckle-tracking echocardiography study416Association between biochemical markers of lipid profile and inflammatory reaction and stiffness of the vascular wall in hypertensive patients with abdominal obesity417Multiple common co-morbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress and myocardial stiffening418Investigating the cardiovascular effects of antiretroviral drugs in a lean and high fat/sucrose diet rat model of obesity419Statins in the treatment of non-alcoholic steatohepatitis (NASH). Our experience from a 2-year prospective study in Constanta County, Romania420Epicardial adipose tissue as a predictor of cardiovascular outcome in patients with ACS undergoing PCI?Arterial and pulmonary hypertension423Dependence between heart rhythm disorers and ID polymorphism of ACE gene in hypertensive patients424Molecular mechanisms underlying the beneficial effects of Urocortin 2 in pulmonary arterial hypertension425Inhibition of TGf-b axis and action of renin-angiotensin system in human ascending aorta aneurysms426Early signs of microcirculation and macrocirculation abnormalities in prehypertension427Vascular smooth muscle cell-expressed Tie-2 controls vascular tone428Cardiac and vascular remodelling in the development of chronic thrombo-embolic pulmonary hypertension in a novel swine modelBiomarkers431Arrhythmogenic cardiomyopathy: a new, non invasive biomarker432Can circulating microRNAs distinguish type 1 and type 2 myocardial infarction?433Design of a high-throughput multiplex proteomics assay to identify left ventricular diastolic dysfunction in diabetes434Monocyte-derived and P-selectin-carrying microparticles are differently modified by a low fat diet in patients with cardiovascular risk factors who will and who will not develop a cardiovascular event435Red blood cell distribution width assessment by polychromatic interference microscopy of thin films in chronic heart failure436Invasive and noninvasive evaluation of quality of radiofrequency-induced cardiac denervation in patients with atrial fibrillation437The effect of therapeutic hypothermia on the level of brain derived neurotrophic factor (BDNF) in sera following cardiopulmonary resustitation438Novel biomarkers to predict outcome in patients with heart failure and severe aortic stenosis439Biological factors linking depression and anxiety to cardiovascular disease440Troponins and myoglobin dynamic at coronary arteries graftingInvasive, non-invasive and molecular imaging443Diet composition effects on the genetic typing of the mouse ob mutation: a micro-ultrasound characterization of cardiac function, macro and micro circulation and liver steatosis444Characterization of pig coronary and rabbit aortic lesions using IV-OCT quantitative analysis: correlations with histologyGene therapy and cell therapy447Enhancing the survival and angiogenic potential of mouse atrial mesenchymal cells448VCAM-1 expression in experimental myocardial infarction and its relation to bone marrow-derived mononuclear cell retentionTissue engineering451Advanced multi layered scaffold that increases the maturity of stem cell-derived human cardiomyocytes452Response of engineered heart tissue to simulated ischemia/reperfusion in the presence of acute hyperglycemic conditions453Serum albumin hydrogels prevent de-differentiation of neonatal cardiomyocytes454A novel paintbrush technique for transfer of low viscosity ultraviolet light curable cyan methacrylate on saline immersed in-vitro sheep heart [O] . V Garcia-Martinez, C Lopez Sanchez, W Hamed, 2016

1. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases:A cross-sectional and longitudinal analysis [J] . Peter Hoffmann ,Victoria Jung ,Rouven Behnisch . 世界胃肠病学杂志：英文版 . 2020,第46期

2. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history [J] . Salvatore Magrì ,Danilo Paduano ,Fabio Chicco . 世界胃肠病学杂志：英文版 . 2019,第37期

3. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic(type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease [J] . Bharat K Puchakayala ,Siddharth Verma ,Pushpjeet Kanwar . 世界肝病学杂志：英文版（电子版） . 2015,第25期

4. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: a review article [J] . Che-yung Chao ,Robert Battat ,Alex Al Khoury . 世界胃肠病学杂志：英文版 . 2016,第34期

5. Ursodeoxycholic acid as a means of preventing atherosclerosis,steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease [J] . Maria Nadinskaia ,Marina Maevskaya ,Vladimir Ivashkin . 世界胃肠病学杂志：英文版 . 2021,第10期

6. 专利药:蛋氨酸组合物在治疗心脑血管疾病中的应用(见专利证书) [C] . 倪荣聪 . 世界中联中医特色诊疗研究专业委员会换届大会暨第九届中医特色诊疗国际学术年会 . 2016

7. 基于呼出气体及其冷凝物中标志物筛查肺部疾病方法研究 [A] . 王林 . 2013